Hand, Foot and Mouth Disease Clinical Trial
Official title:
A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months
Since its discovery in 1969, enterovirus 71 (EV71) has been recognised as a frequent cause
of epidemics of hand-foot-mouth disease (HFMD) associated with severe neurological sequelae
in a small proportion of cases. There has been a significant increase in EV71 epidemic
activity throughout the Asia-Pacific region since 1997. Recent HFMD epidemics in this region
have heen associated with a severe from of brainstem encephalitis associated with pulmonary
oedema and high case-fatality rates.
The data from the phase 1 and 2 trials suggested that the inactivated EV71 vaccine had a
clinically acceptable safety and good immunogenicity for healthy Chinese children and
infants. According to the immunogenicity and safety results, the 320U with adjuvant with
immunizing schedule of two doses (per 28 day) will be applied in phase 3 clinical trial.
Status | Completed |
Enrollment | 10245 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months to 35 Months |
Eligibility |
Inclusion Criteria: Only subjects fulfilling all of the following criteria will be eligible for the study: - Healthy children aged from 6 to 35 months old - General good health as established by medical history and physical examination - The subjects' guardians are able to understand and sign the informed consent - Had never received the vaccine against EV71 - The subjects' guardians allow to comply with the requirements of the protocol - Available for all visits scheduled in this study - Subjects with temperature <=37.0°C on axillary setting Exclusion Criteria: Subjects will not be eligible for the study if any of the following criteria is met: - Subject who has a medical history of HFMD - Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine - Family history of seizures or progressive neurological disease - Family history of congenital or hereditary immunodeficiency - Severe malnutrition or hypogenesis - Major congenital defects or serious chronic illness, including perinatal brain damage - Autoimmune disease - Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws - Asplenia, functional asplenia, or splenic excision - History of asthma, angioneurotic edema, diabetes or malignant tumour - History of thyroidectomy, or thyroid disease in last 12 months - Any acute infections in last 7 days - Any prior administration of immunodepressant or corticosteroids in last 6 months - Any prior administration of blood products in last 3 months - Any prior administration of other research vaccines or medicines in last 1 month - Any prior administration of attenuated live vaccine in last 15 days - Any prior administration of subunit or inactivated vaccines in last 7 days - Under the anti-TB prevention or therapy - Subjects with temperature >37.0°C on axillary setting - Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives Exclusion Criteria for the second dose: Subjects will not be eligible for the second dose if any of following adverse events happened after the first dose. They can continue other process of the study without the second dose vaccination according to the opinion of the investigator. - Had any serious adverse events related to the first dose of inactivated vaccine (vero cell) against EV71 within 7 days - Hypersensitivity reactions after vaccination (including urticaria/rashes that occur within 30 minutes after inoculation) - Anaphylaxis after vaccination - Any confirmed or suspected autoimmune disease or immune deficiency diseases, including human immunodeficiency virus (HIV) infection - Any condition that in the opinion of the investigator, or IRB |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
China | Chaoyang Distinct Center for Disease Control and Prevention | Beijing | |
China | Donghai County Center for Disease Control and Prevention | Lianyungang | Jiangsu |
China | Pizhou County-Level City Center for Disease Control and Prevention | Xuzhou | Jiangsu |
China | Baoying County Center for Disease Control and Prevention | Yangzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Province Centers for Disease Control and Prevention | Bejing Vigoo Biological Co., LTD |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the incidence density of the EV71-associated diseases in the vaccine group and placebo group. | compare the incidence density of the EV71-associated diseases between the vaccine group and placebo group in Chinese children aged 6-35 months. | begin at day 56 up to 14 months | No |
Secondary | the frequency of all the adverse events in vaccine group and placebo group. | compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group. | up to 14 months | Yes |
Secondary | Seropositive rate of the vaccine group | calculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. | 8 months after first vaccination | No |
Secondary | Seroconversion rate of the vaccine group | calculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. | 8 months after first vaccination | No |
Secondary | GMT of the vaccine group | calculate the geometric mean titre (GMT) of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. | 8 months after first vaccination | No |
Secondary | Seropositive rate of the vaccine group | calculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination. | 14 months after first vaccination | No |
Secondary | Seroconversion rate of the vaccine group | calculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination. | 14 months after first vaccination | No |
Secondary | GMT of the vaccine group | calculate the geometric mean titre (GMT) of the vaccine group in Chinese children aged 6-35 months at month 14 after first vaccination. | 14 months after first vaccination | No |
Secondary | Seropositive rate of the vaccine group and placebo group | compare the seropositive rate of the vaccine group and placebo group in healthy children aged 6-35 months. | 28 days after the second vaccination | No |
Secondary | Seroconversion rate of the vaccine group and placebo group | compare the Seroconversion rate of the vaccine group and placebo group in healthy children aged 6-35 months. | 28 days after the second vaccination | No |
Secondary | GMT of the vaccine group and placebo group | compare the geometric mean titre (GMT) of the vaccine group and placebo group in healthy children aged 6-35 months. | 28 days after the second vaccination | No |
Secondary | GMI of the vaccine group and placebo group | compare the geometric mean fold increase (GMFI) of the vaccine group and placebo group in healthy children aged 6-35 months. | 28 days after the second vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06063057 -
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
|
Phase 1/Phase 2 | |
Completed |
NCT04133584 -
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine
|
Phase 4 | |
Completed |
NCT03241030 -
Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial
|
Phase 2 | |
Completed |
NCT01255124 -
Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children
|
N/A | |
Completed |
NCT03873740 -
Immunogenicity and Safety of Two Different Commercial EV71 Vaccines
|
Phase 4 | |
Completed |
NCT05637229 -
A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
|
||
Recruiting |
NCT06146088 -
Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine
|
Phase 4 | |
Active, not recruiting |
NCT06209398 -
Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine
|
Phase 4 | |
Recruiting |
NCT01175915 -
A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Recruiting |
NCT01145664 -
A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease
|
N/A | |
Completed |
NCT01182532 -
A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Completed |
NCT03281174 -
Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine
|
N/A | |
Completed |
NCT03582761 -
Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71
|
Phase 4 | |
Completed |
NCT03903926 -
Efficacy Trial of a Commercial EV71 Vaccine
|
Phase 4 | |
Completed |
NCT02001233 -
A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
|
||
Completed |
NCT03909074 -
Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months
|
Phase 3 | |
Completed |
NCT01769794 -
Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study
|
N/A | |
Recruiting |
NCT01182025 -
A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Recruiting |
NCT06263439 -
Surveillance of HFMD in Pediatric Outpatients
|
||
Not yet recruiting |
NCT05397587 -
An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell)
|
Phase 4 |